Cartesian Therapeutics (RNAC) Corporate presentation summary

Clinical pipeline and lead asset

• Lead asset Descartes-08 is an mRNA CAR T-cell therapy showing deep, durable responses in myasthenia gravis (MG) for 12 months after a single outpatient course, without lymphodepletion.

• Phase 3 AURORA trial in MG targets a $1B+ market, with expansion planned into myositis and pediatric autoimmune diseases.

• Phase 2 SLE trial showed strong efficacy, supporting broader applicability across autoimmune diseases.

• Descartes-08 is granted FDA orphan, RMAT, and RPDD designations for various indications.

• In-house US manufacturing supports commercial readiness and margin optimization.

Clinical efficacy and safety

• In MG, Descartes-08 achieved an average MG-ADL reduction of 5.5 points at Month 4, maintained through Month 12, with 83% maintaining meaningful response.

• Biologic-naïve MG patients saw even greater benefit, with 100% maintaining response at Month 12.

• Safety profile supports outpatient use, with most adverse events mild and resolving within 24 hours; no AEs after Month 3 and no increased infections.

• Retreatment in MG led to sustained or deepened responses up to 2 years.

• SLE trial showed 100% LLDAS response at Month 3, with no serious adverse events.

Market opportunity and differentiation

• MG market estimated at 106,000 US patients, with Descartes-08 positioned as a disease-modifying, single-course therapy versus chronic biologics.

• Myositis expansion targets 80,000 US patients, with 60% eligible for third-line+ treatment, representing a multi-billion-dollar opportunity.

• Descartes-08 offers outpatient administration, no lymphodepletion, and redosing flexibility, differentiating it from existing therapies.